A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Bernstock, Joshua D; Lee, Yang-ja; Peruzzotti-Jametti, Luca; Southall, Noel; Johnson, Kory R; Maric, Dragan; Volpe, Giulio; Kouznetsova, Jennifer; Zheng, Wei; Pluchino, Stefano; Hallenbeck, John M
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 36:Issue 2(2016)
• Page Start: 426
• Page End: 441
• Publication Date: 2016-02
• Subjects: High-throughput assay development -- miRNA -- neuroprotection -- SUMO conjugation -- translational research; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X15609939
• Languages: English
• ISSNs: 0271-678X

Abstract

The conjugation/de-conjugation ofS mallU biquitin-likeMo difier (SUMO) has been shown to be associated with a diverse set of physiologic/pathologic conditions. The clinical significance and ostensible therapeutic utility offered via the selective control of the global SUMOylation process has become readily apparent in ischemic pathophysiology. Herein, we describe the development of a novel quantitative high-throughput screening (qHTS) system designed to identify small molecules capable of increasing SUMOylation via the regulation/inhibition of members of the microRNA (miRNA)-182 family. This assay employs a SHSY5Y human neuroblastoma cell line stably transfected with a dual firefly-Renilla luciferase reporter system for identification of specific inhibitors of either miR-182 or miR-183. In this study, we have identified small molecules capable of inducing increased global conjugation of SUMO in both SHSY5Y cells and rat E18-derived primary cortical neurons. The protective effects of a number of the identified compounds were confirmed via an in vitro ischemic model (oxygen/glucose deprivation). Of note, this assay can be easily repurposed to allow high-throughput analyses of the potential drugability of other relevant miRNA(s) in ischemic pathobiology.